The Liver Disease and Drug Metabolism Panel which includes CYP2C19, UGT1A1, HFE, and other genes, covers genetic variables impacting liver disorders and drug metabolism, which are relevant in gastrointestinal (Liu et al., 2022) and could be very relevant to clinical practice due to the liver’s crucial function in digestion and drug processing. The gene discussed is CYP2C19; the disease is liver disorder.